Treatment-related adverse events of antibody drug-conjugates in clinical trials
Abstract Background Antibody–drug conjugates (ADCs) aim to enhance the therapeutic index of cytotoxic agents but can cause unexpected toxicities. This study evaluated adverse events (AEs) from phase 1 trials at The Royal Marsden Drug Development Unit (DDU) over a decade and pivotal phase 2 and 3 tri...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BMC
2025-07-01
|
| Seri Bilgileri: | Journal of Hematology & Oncology |
| Konular: | |
| Online Erişim: | https://doi.org/10.1186/s13045-025-01720-3 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|